RenovoRx, Inc. (RNXT) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Mountain View, CA, 미국. 현재 CEO는 Shaun R. Bagai.
RNXT 을(를) 보유 IPO 날짜 2021-08-26, 10 명의 정규직 직원, 에 상장 NASDAQ Capital Marke, 시가총액 $36.15M.
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
